Adma Biologics (ADMA) Stock Price, Quote & News

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute e...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 478 5552

Fax: 201 478 5553

Website: www.admabiologics.com

Address:

465 State Route 17, Ramsey, United States

BabetteCH Jan. 7 at 8:45 PM

$ADMA sector rotation into biotech? Looks like…

0 · Reply

MoneyGroupLLC Jan. 7 at 6:41 PM

Enter: $ADMA Calls Strike Price: $19 Expiry Date: FEB 20 2026 Buy in Price: $1.19 - $1.75 Sell Price: $2.00 Profit : +68% (Turn every $1 into $1.68) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

TPower Jan. 7 at 12:21 PM

$ADMA Preliminary year 2025 results can come any time now until mid January

1 · Reply

ST_Tropez_Trading Jan. 7 at 10:44 AM

$ADMA Wen 30+ ?

0 · Reply

GoldmanSlaps Jan. 7 at 3:55 AM

$ADMA soon

0 · Reply

biffermeister Jan. 6 at 6:55 PM

$ADMA they will have to handily beat expectations and guide higher to resume the uptrend.

0 · Reply

apc62657 Jan. 6 at 5:30 PM

$ADMA If company hits their projected annual ebitda of $235 million they would need 4th qtr ebitda of $78 million. Adam pretty pretty pretty good about hitting or exceeding estimates. Should be a blow out quarter

1 · Reply

ncost1 Jan. 6 at 3:36 PM

$ADMA this things needs News or earnings to get us to the next level

1 · Reply

MoneyGroupLLC Jan. 6 at 8:46 AM

Enter: $ADMA Calls Strike Price: $18 Expiry Date: FEB 20 2026 Buy in Price: $1.42 - $1.49 Sell Price: $2.66 Profit : +87% (Turn every $1 into $1.87) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

uhhhhhhhhhhh Jan. 5 at 7:29 PM

$ADMA well at least adma can remain neutral while biotech broadly sells off. The adma classic

0 · Reply

ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

Nov 20, 2025, 4:35 PM EST - 6 weeks ago

ADMA Biologics: Why The Dip To $16 Resets The Buy Case

Nov 6, 2025, 3:31 AM EST - 2 months ago

ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 2 months ago

ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 7:00 AM EDT - 2 months ago

ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 2:30 PM EDT - 3 months ago

3 Biotech Stocks I Am Accumulating

HRMY INCY SNDX XBI

Sep 3, 2025, 6:12 AM EDT - 4 months ago

ADMA Biologics: Strong Product Mix, Growing Margins And Compelling Upside

Aug 10, 2025, 9:15 AM EDT - 5 months ago

ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform

Aug 8, 2025, 3:58 PM EDT - 5 months ago

ADMA Biologics: A Better Quarter Than Headline Numbers

Aug 6, 2025, 9:14 PM EDT - 5 months ago

ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 5 months ago

ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 7:00 AM EDT - 5 months ago

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 15, 2025, 4:11 AM EDT - 7 months ago

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)

May 9, 2025, 3:54 AM EDT - 8 months ago

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss

May 7, 2025, 11:05 PM EDT - 8 months ago

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 8 months ago

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:00 AM EDT - 9 months ago

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 28, 2025, 7:00 AM EDT - 9 months ago

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

Apr 7, 2025, 7:00 AM EDT - 9 months ago

ADMA Biologics Statement on Tariffs

Mar 21, 2025, 3:04 PM EDT - 10 months ago

ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential

Mar 4, 2025, 1:50 PM EST - 11 months ago

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

Mar 3, 2025, 6:24 PM EST - 11 months ago

ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 11 months ago

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 7:00 AM EST - 11 months ago

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

Feb 25, 2025, 7:00 AM EST - 11 months ago

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 6, 2025, 1:46 PM EST - 11 months ago

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add

Dec 20, 2024, 7:00 AM EST - 1 year ago

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

Dec 13, 2024, 5:15 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Dec 11, 2024, 6:15 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Dec 9, 2024, 5:45 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm

Dec 7, 2024, 5:30 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm

Dec 5, 2024, 2:15 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm

Dec 3, 2024, 3:15 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm

Dec 2, 2024, 8:30 AM EST - 1 year ago

ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV

Dec 1, 2024, 3:15 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm

Nov 29, 2024, 12:30 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Committing Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 26, 2024, 11:00 AM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

$The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions$

Nov 25, 2024, 1:00 PM EST - 1 year ago

The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions

Nov 24, 2024, 2:00 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

BabetteCH Jan. 7 at 8:45 PM

$ADMA sector rotation into biotech? Looks like…

0 · Reply

MoneyGroupLLC Jan. 7 at 6:41 PM

0 · Reply

TPower Jan. 7 at 12:21 PM

$ADMA Preliminary year 2025 results can come any time now until mid January

1 · Reply

ST_Tropez_Trading Jan. 7 at 10:44 AM

$ADMA Wen 30+ ?

0 · Reply

GoldmanSlaps Jan. 7 at 3:55 AM

$ADMA soon

0 · Reply

biffermeister Jan. 6 at 6:55 PM

$ADMA they will have to handily beat expectations and guide higher to resume the uptrend.

0 · Reply

apc62657 Jan. 6 at 5:30 PM

1 · Reply

ncost1 Jan. 6 at 3:36 PM

$ADMA this things needs News or earnings to get us to the next level

1 · Reply

MoneyGroupLLC Jan. 6 at 8:46 AM

0 · Reply

uhhhhhhhhhhh Jan. 5 at 7:29 PM

$ADMA well at least adma can remain neutral while biotech broadly sells off. The adma classic

0 · Reply

BabetteCH Jan. 5 at 3:13 PM

$ADMA https://ir.admabiologics.com/news-releases/news-release-details/adma-biologics-present-jp-morgan-healthcare-conference-january

1 · Reply

StockBraker Jan. 5 at 1:44 PM

$ADMA Petrone?? Nachman?? Where are you guys???

0 · Reply

MoneyGroupLLC Jan. 4 at 2:47 PM

Enter: $ADMA Calls Strike Price: $18 Expiry Date: FEB 20 2026 Buy in Price: $1.42 - $2.10 Sell Price: $2.68 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

gorwell Jan. 4 at 2:06 AM

$ADMA seeing tutes trim makes me think that the trade will be stalled for a bit yet bc of uncertainty in the country. And maybe lack of cats. Profitable and (now) boring

2 · Reply

BabetteCH Jan. 3 at 11:44 AM

$ADMA https://coincodex.com/stock/ADMA/price-prediction/ >> long-term forecast 🚀

0 · Reply

Numpsey Jan. 2 at 6:37 PM

$ADMA No volume. RSI reaching oversold! Bounce 17.44-17.50 Give or take. Tough to watch , but nothing has changed.

1 · Reply

USMAgrad Jan. 2 at 6:17 PM

$ADMA Can not believe this has been driven under $18… AGAIN🥴

0 · Reply

Comingle Jan. 2 at 6:05 PM

$ADMA tough week

0 · Reply

ncost1 Jan. 2 at 3:49 PM

$ADMA business update was Jan 13 last year so maybe in a week or two get guidance.

0 · Reply

Disvan Jan. 2 at 3:17 PM

$ADMA camaan dip further, got an order for 17s.

0 · Reply

MoneyGroupLLC Jan. 2 at 8:54 AM

Enter: $ADMA Calls Strike Price: $19 Expiry Date: FEB 20 2026 Buy in Price: $1.55 - $1.95 Sell Price: $4.08 Profit : +109% (Turn every $1 into $2.09) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HarrierduBois Jan. 1 at 9:02 PM

$IDYA $ADMA starting long term positions in these two will be the first investments I make in 2026.

1 · Reply

Market Cap	4.26B
Revenue (ttm)	426.45M
Net Income (ttm)	197.67M
EPS (ttm)	N/A
PE Ratio	30.92
Forward PE	22.24
Profit Margin	46.35%
Debt to Equity Ratio	0.16

Volume	1,985,849
Avg Vol	3,081,584
Day's Range	N/A - N/A
Shares Out	238.00M
Stochastic %K	37%
Beta	0.47
Analysts	Strong Sell
Price Target	$30.00